The Global Deep Brain Stimulation Devices Market size was estimated at USD 1.40 billion in 2024 and is projected to reach USD 2.50 billion by 2030, growing at a CAGR of 10.2% from 2025 to 2030.This robust growth is primarily driven by the increasing prevalence of neurological disorders such as Parkinson’s disease and epilepsy, along with the continuous introduction of technologically advanced DBS products. In addition, the rising use of DBS as an add-on therapy and the growing preference for minimally invasive surgical procedures are significantly contributing to market expansion.

The increasing burden of neurological and lifestyle-related disorders is expected to further accelerate market growth over the forecast period. For example, according to the World Stroke Organization (WSO) global stroke fact sheet for 2022, more than 12.2 million new stroke cases are reported each year worldwide. Furthermore, the data indicates that globally, one in four individuals aged 25 years or older is likely to experience a stroke during their lifetime. These alarming statistics highlight the urgent need for effective prevention and treatment solutions, thereby supporting the growing adoption of advanced neurological therapies such as deep brain stimulation. As a result, the market is anticipated to witness sustained growth in the near future.

Additionally, factors such as increased external funding for research and development, strategic collaborations, regulatory approvals from bodies such as the FDA, and the rising demand for minimally invasive surgeries are further propelling market growth. For instance, in April 2022, a major clinical trial was launched at Southmead Hospital in Bristol to evaluate a novel miniaturized deep brain stimulation device known as the Picostim DBS system. The key aim of this trial is to reduce complications and lower the overall costs associated with DBS surgery by introducing this innovative technology. The development of such advanced devices has the potential to simplify existing DBS procedures, making them faster, safer, and more cost-effective. This advancement could significantly expand access to DBS therapy, particularly for patients with Parkinson’s disease, by improving affordability and availability. Consequently, such ongoing developments and initiatives are expected to boost the demand for deep brain stimulation devices in the near future.

Key Market Trends & Insights:

• North America accounted for the largest share of the global deep brain stimulation devices market, capturing 50.55% of the total market revenue in 2024. This dominance can be attributed to factors such as the high prevalence of neurological disorders, the presence of advanced healthcare infrastructure, early adoption of innovative medical technologies, and favorable reimbursement policies across the region.

• Within North America, the U.S. deep brain stimulation devices market is expected to continue dominating throughout the forecast period. This leadership position is supported by strong investments in healthcare, a well-established network of hospitals and specialized neurological centers, increasing awareness regarding advanced treatment options, and the presence of key market players actively engaged in product development and commercialization.

• Based on product type, the dual-channel segment emerged as the leading category in the market, accounting for a share of 56.9% in 2024. The dominance of this segment is largely driven by its ability to offer enhanced stimulation flexibility, improved therapeutic outcomes, and greater precision in managing complex neurological conditions, making it a preferred choice among healthcare professionals.

• In terms of end use, hospitals dominated the overall deep brain stimulation devices market, holding a share of 51.45% in 2024. This can be attributed to the availability of advanced surgical facilities, skilled neurosurgeons, and comprehensive post-operative care within hospital settings, which collectively support the higher adoption of deep brain stimulation procedures.

• On the basis of application, the Parkinson’s disease segment led the market with a significant share of 64.98% in 2024. The high prevalence of Parkinson’s disease, coupled with the increasing adoption of deep brain stimulation as an effective treatment option for managing motor symptoms in advanced cases, has strongly contributed to the dominance of this application segment.

Order a free sample PDF of the Deep Brain Stimulation Devices Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 1.40 Billion

• 2030 Projected Market Size: USD 2.50 Billion

• CAGR (2025-2030): 10.2%

• North America: Largest market in 2024

Key Companies & Market Share Insights:

The deep brain stimulation (DBS) devices market is characterized by intense competition and a moderately fragmented structure, with the presence of a few well-established players such as Abbott, Boston Scientific Corporation, and Medtronic, alongside several emerging entrants. These leading companies hold a strong position in the market due to their extensive product portfolios, robust research and development capabilities, and well-established global distribution networks.

Key players operating in the DBS devices market are increasingly concentrating on strategic initiatives such as new product launches, continuous technological advancements, and various inorganic growth strategies, including mergers and acquisitions, to reinforce their market presence and expand their competitive edge. Such strategies enable companies to enhance their technological capabilities, broaden their customer base, and strengthen their overall market positioning.

For instance, in July 2023, Boston Scientific Corporation received FDA approval for its Vercise Neural Navigator 5 Software. This advanced software, when used in combination with the Vercise Genus Deep Brain Stimulation (DBS) systems, is designed to deliver critical data that supports clinicians in optimizing treatment outcomes for patients suffering from Parkinson’s disease or essential tremor. The introduction of this innovative solution is expected to improve the precision, personalization, and overall effectiveness of DBS therapy, thereby offering significant benefits to patients managing these neurological conditions.

Key Players

• Medtronic

• Boston Scientific Corporation

• Abbott

• Aleva Neurotherapeutics

• Newronika S.p.A.

• Beijing PINS Medical Co., Ltd.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The deep brain stimulation (DBS) market is expected to witness steady growth driven by the rising burden of neurological disorders, increasing acceptance of advanced neuromodulation therapies, and continuous technological innovations. Growing preference for minimally invasive procedures, along with expanding clinical applications of DBS, is further supporting market expansion. In addition, strong research and development activities, regulatory approvals, and strategic initiatives by key market players are enhancing treatment precision and patient outcomes. Overall, the market outlook remains positive, supported by improving healthcare infrastructure and increasing awareness of DBS as an effective therapeutic option for complex neurological conditions.